A two-week course of antiviral therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin, started within 7 days of showing COVID-19 symptoms, is safe and more effective at reducing the duration of viral shedding than lopinavir-ritonavir alone in patients with mild to moderate illness, according to the first randomised trial of this triple combination therapy involving 127 adults (aged 18 and older) from six public hospitals in Hong Kong.
source https://www.pharmatutor.org/pharma-news/2020/new-triple-antiviral-drug-combination-shows-early-promise-for-treating-covid-19-in-clinical-trial
No comments:
Post a Comment